Key takeaways
- In South Africa, Diane-35 is approved for moderate to severe androgen-sensitive acne, excess hair growth (hirsutism), or both, including in people with PCOS. SAHPRA-approved Diane-35 information.
- For acne, the label keeps it for cases where creams and gels, or antibiotics taken by mouth, are not considered appropriate. South African indication.
- It is also a contraceptive pill, so it replaces your hormonal contraception rather than being added to it. Local product information.
- Europe’s medicines regulator found a higher risk of clots in the veins than with pills containing levonorgestrel, and still kept a place for it in treating acne and hirsutism. EMA benefit-risk review.
Diane-35 is often called “the PCOS pill”, usually by people dealing with acne that flares before a period or with coarse hair on the chin and upper lip. Its history shows why that nickname is too loose. In 2013, France’s medicines agency suspended it after a national review highlighted serious clotting events and widespread use of Diane-35 purely as a contraceptive. A Europe-wide review then kept it on the market, but only for moderate to severe acne linked to androgens and for hirsutism, and only for acne that other treatments had failed to control. EMA review.
The South African professional information, revised on 21 July 2022, uses similar wording for acne and hirsutism, and allows it for acne when creams, gels or antibiotics taken by mouth are not considered appropriate. Each active tablet contains cyproterone acetate, an anti-androgen, and ethinylestradiol, an oestrogen.
Does Diane-35 treat PCOS itself?
No. It treats two things PCOS can cause, acne and excess hair, rather than the condition behind them.
The South African indication mentions PCOS, but only as the setting for the acne or hirsutism it treats. It is not presented as a treatment for the metabolic or fertility sides of the condition. Local prescribing information.
It is also a contraceptive, and the label rules it out during pregnancy and breastfeeding. Anyone trying to conceive needs a plan for their skin and hair that does not rely on it.
If facial hair is the main problem, our eflornithine guide covers a cream that acts on the hair follicle itself. For acne that keeps coming back, the isotretinoin article weighs another option, with very different precautions.
When is a hormonal acne treatment worth considering?
It is one option among several, and the South African label keeps it for acne where creams or antibiotics are not suitable.
The American Academy of Dermatology’s guideline includes combined contraceptive pills among its supported acne treatments, next to creams, antibiotics and other medicines taken by mouth. AAD acne guideline. For Diane-35 itself, the European review counted more than 30 clinical trials supporting its use in moderate to severe acne and hirsutism, and found the evidence limited for acne without androgen-related features. EMA review.
It is also slow. The South African label puts the time to relief at three months or more, with acne and oily skin usually responding before excess hair does. South African product information.
| Main treatment goal | Useful question |
|---|---|
| Persistent inflammatory acne | Are topical or antibiotic options suitable, and what has already failed? |
| Acne with unwanted facial hair | Would an anti-androgen approach address both concerns? |
| Contraception without acne or hirsutism | Is a contraceptive chosen for that purpose a better fit? |
| Trying to conceive | What non-contraceptive plan addresses the symptoms? |
How should the blood-clot warning be interpreted?
The increase is real, but a higher relative risk does not mean a clot is likely for you.
Observational studies reviewed by the EMA put the risk of a clot in the veins at 1.5 to 2 times that of combined pills containing levonorgestrel, and possibly similar to pills containing gestodene, desogestrel or drospirenone. So the comparison is with other contraceptive pills rather than with taking nothing. A multiplier also says nothing about your own odds, which depend on where you start. EMA review.
The excess risk is highest in the first year of use and after restarting following a break of a month or more. EMA assessment. The South African label lists what raises it further: getting older, smoking (particularly over the age of 35), a parent or sibling who had a clot at a relatively young age, obesity, and major surgery, leg surgery, serious injury or long spells in bed. For planned surgery it recommends stopping at least four weeks beforehand and restarting only two weeks after you are fully mobile again. A history of migraine with aura also needs mentioning, because the label treats migraine with focal neurological symptoms as a reason not to use it.
The South African information also warns that people using Diane-35 are likely to include some with an inborn higher cardiovascular risk, and it gives polycystic ovary syndrome as the example. Prescribers are asked to check periodically whether treatment still needs to continue. South African product information.
According to the same label, 1 to 2% of clots in the veins are fatal. That is why new pain or swelling in one leg, unexplained breathlessness or chest pain, or sudden neurological symptoms such as weakness or difficulty speaking need urgent medical help.
What should be checked before starting or changing packs?
Which product you have, how it fits your contraception, and what else you take.
Pack instructions can differ between presentations, so follow the leaflet in the pack you have and your prescriber’s advice rather than a generic online pill calendar. The South African information is specific about missed tablets: once a hormone-containing tablet is more than 12 hours late, seven days of extra barrier contraception are needed. It also names medicines that can make Diane-35 less effective, among them phenytoin, carbamazepine, rifampicin and St John’s wort, and notes that several types of HIV and hepatitis C medicine can raise or lower its hormone levels. South African product information.
Do not combine it with another hormonal contraceptive. The EMA points out that doing so means a higher dose of oestrogen and a higher clot risk. EMA review.
Regulatory note
South Africa, checked 8 September 2026: The cited South African Diane-35 professional information lists it as Schedule 4. Its PCOS wording concerns treatment of specified androgen-related symptoms, not a general PCOS cure.
Do and don’t
Do: Talk about the skin problem and your contraception or pregnancy plans in the same conversation.
Don’t: Ignore new clot symptoms, double up on hormonal contraceptives, or drop follow-up because your skin has cleared.
